All Posts: mind
-
Georgetown Clinical Trial Testing Nilotinib in Alzheimer’s Disease Begins
A clinical trial to examine the effect of nilotinib on clinical outcomes and biomarkers in people with mild to moderate Alzheimer’s disease has opened at Georgetown University Medical Center (GUMC).
Category: News Release
-
Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
TORONTO (July 27, 2016) — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, […]
Category: News Release
-
First-of-Its-Kind Study Explains Why Rest is Critical After A Concussion
Doctors who order several days of rest after a person suffers a concussion are giving sound advice, say researchers, and new data from animal models explains why. Georgetown University Medical Center neuroscientists say rest — for more than a day — is critical for allowing the brain to reset neural networks and repair any short-term injury. The new study in mice also shows that repeated mild concussions with only a day to recover between injuries leads to mounting damage and brain inflammation that remains evident a year after injury.
Category: News Release
-
Could Blood pressure drugs have a role in Alzheimer's Disease treatment?
WASHINGTON — In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer’s disease, say researchers at Georgetown University Medical Center (GUMC) and the National Institutes of Health.
Category: News Release
-
Researchers Report First Therapy Appearing to Reverse Decline in Parkinson’s
OCTOBER 17, 2015 – An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC). The drug, nilotinib (known as Tasigna® by Novartis) also led to statistically significant and encouraging changes in toxic […]
Category: GUMC Stories
-
Cancer Drug Improved Cognition and Motor Skills in Small Parkinson’s Clinical Trial
CHICAGO (Oct. 17, 2015) — An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington. In addition, the drug, nilotinib (Tasigna® by Novartis), led to statistically significant […]
Category: News Release
-
Resveratrol Impacts Alzheimer’s Disease Biomarker
WASHINGTON — The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.
Category: News Release
-
Patients Drive Support Of Parkinson’s Fellowship Program
March 2, 2015 — Twelve years ago, Rick Schena, a United Airlines pilot, felt something amiss in the body he has always been so in tune with — the onset of tremors, some rigidity, and issues with processing vision. Six years ago he was diagnosed with Parkinson’s. This was devastating to the speed junkie who […]
Category: GUMC Stories
-
Researcher Debunks Alzheimer's Prevailing Development Theory
(October 31, 2014) – New research that dramatically alters the prevailing theory of how Alzheimer’s disease develops has been published online today by Georgetown researchers in the journal Molecular Neurodegeneration. The research also helps explains why some people with plaque buildup in their brains don’t develop dementia, and shows the potential of a cancer drug […]
Category: GUMC Stories
-
Tau, Not Amyloid-beta, Triggers Neuronal Death Process in Alzheimer’s
WASHINGTON (Oct. 31, 2014) — New research points to malfunctioning tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer’s disease. The finding, which dramatically alters the prevailing theory of Alzheimer’s development, also explains why some people with plaque build-up in their brains don’t have dementia. The […]
Category: News Release